Bing Chen

7PUBLICATIONS
5CO-AUTHORS
Molecular targetsMedical infection agents (incl. prions)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMedical mycology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 13, 2026
The development of novel chimeric antigen receptor gamma-delta T cells against multiple myeloma and single-cell RNA sequencing analysis.

|May 10, 2025
ZMYND8 Reads H3K36me2 to Activate CEBPE Transcription and Suppress Multiple Myeloma Progression through the Inhibition of Adaptive UPR Pathways.

Jiaxuan Xu, Xiaoqing Dong, Yue Peng

|Jul 03, 2024
Development of novel humanized CD19/BAFFR bicistronic chimeric antigen receptor T cells with potent antitumor activity against B-cell lineage neoplasms.

Sungui Wu, Qian Luo, Feiyu Li

|Mar 15, 2024
Construction and validation of an 18F-FDG-PET/CT-based prognostic model to predict progression-free survival in newly diagnosed multiple myeloma patients.

Xiaoqing Dong, Ruoyi Wang, Xiuhua Ying

|Oct 28, 2023
Current Advances and Future Strategies for BCL-2 Inhibitors: Potent Weapons against Cancers.

Jiaxuan Xu, Xiaoqing Dong, David C S Huang

|Sep 02, 2022
Formosanin C induces autophagy-mediated apoptosis in multiple myeloma cells through the PI3K/AKT/mTOR signaling pathway.

Ping Chen, Sungui Wu, Xiaoqing Dong

Pageof 2

Frequent Collaborators

2 joint publications

Xiaoqing Dong

1 joint publications

Quan Zhao

1 joint publications

Sungui Wu

1 joint publications

Taochao Tan